• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体细胞选择区分致癌基因和肿瘤抑制基因。

Somatic selection distinguishes oncogenes and tumor suppressor genes.

机构信息

College of Health Solutions, Arizona State University, Phoenix, AZ, 85004, USA.

Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, 85281, USA.

出版信息

Bioinformatics. 2020 Mar 1;36(6):1712-1717. doi: 10.1093/bioinformatics/btz851.

DOI:10.1093/bioinformatics/btz851
PMID:32176769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7703750/
Abstract

MOTIVATION

Functions of cancer driver genes vary substantially across tissues and organs. Distinguishing passenger genes, oncogenes (OGs) and tumor-suppressor genes (TSGs) for each cancer type is critical for understanding tumor biology and identifying clinically actionable targets. Although many computational tools are available to predict putative cancer driver genes, resources for context-aware classifications of OGs and TSGs are limited.

RESULTS

We show that the direction and magnitude of somatic selection of protein-coding mutations are significantly different for passenger genes, OGs and TSGs. Based on these patterns, we develop a new method (genes under selection in tumors) to discover OGs and TSGs in a cancer-type specific manner. Genes under selection in tumors shows a high accuracy (92%) when evaluated via strict cross-validations. Its application to 10 172 tumor exomes found known and novel cancer drivers with high tissue-specificities. In 11 out of 13 OGs shared among multiple cancer types, we found functional domains selectively engaged in different cancers, suggesting differences in disease mechanisms.

AVAILABILITY AND IMPLEMENTATION

An R implementation of the GUST algorithm is available at https://github.com/liliulab/gust. A database with pre-computed results is available at https://liliulab.shinyapps.io/gust.

SUPPLEMENTARY INFORMATION

Supplementary data are available at Bioinformatics online.

摘要

动机

癌症驱动基因的功能在不同的组织和器官中有很大的差异。区分每个癌症类型的乘客基因、癌基因(OGs)和肿瘤抑制基因(TSGs)对于理解肿瘤生物学和确定临床可操作的靶点至关重要。尽管有许多计算工具可用于预测潜在的癌症驱动基因,但用于 OG 和 TSG 上下文感知分类的资源有限。

结果

我们表明,蛋白质编码突变的体细胞选择的方向和幅度对于乘客基因、OG 和 TSG 有显著的不同。基于这些模式,我们开发了一种新的方法(肿瘤中选择的基因),以特定于癌症类型的方式发现 OG 和 TSG。通过严格的交叉验证评估,肿瘤中选择的基因显示出很高的准确性(92%)。其在 10172 个肿瘤外显子中的应用发现了具有高组织特异性的已知和新的癌症驱动基因。在 13 个在多种癌症类型中共享的 OG 中,我们发现了在不同癌症中选择性参与的功能域,这表明疾病机制存在差异。

可用性和实现

GUST 算法的 R 实现可在 https://github.com/liliulab/gust 获得。一个带有预计算结果的数据库可在 https://liliulab.shinyapps.io/gust 获得。

补充信息

补充数据可在生物信息学在线获得。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b27d/7703750/8c4f6c243798/btz851f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b27d/7703750/1fc42fdd63f1/btz851f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b27d/7703750/8bdec64aff11/btz851f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b27d/7703750/8c4f6c243798/btz851f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b27d/7703750/1fc42fdd63f1/btz851f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b27d/7703750/8bdec64aff11/btz851f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b27d/7703750/8c4f6c243798/btz851f3.jpg

相似文献

1
Somatic selection distinguishes oncogenes and tumor suppressor genes.体细胞选择区分致癌基因和肿瘤抑制基因。
Bioinformatics. 2020 Mar 1;36(6):1712-1717. doi: 10.1093/bioinformatics/btz851.
2
Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data.从泛癌基因组测序数据中进行肿瘤抑制基因和癌基因的统计学鉴定。
Bioinformatics. 2015 Nov 15;31(22):3561-8. doi: 10.1093/bioinformatics/btv430. Epub 2015 Jul 25.
3
DORGE: Discovery of Oncogenes and tumoR suppressor genes using Genetic and Epigenetic features.利用遗传和表观遗传特征发现癌基因和肿瘤抑制基因。
Sci Adv. 2020 Nov 11;6(46). doi: 10.1126/sciadv.aba6784. Print 2020 Nov.
4
Novel ratio-metric features enable the identification of new driver genes across cancer types.新型比率度量特征可识别跨癌症类型的新驱动基因。
Sci Rep. 2022 Jan 7;12(1):5. doi: 10.1038/s41598-021-04015-y.
5
Oncogenes and tumor suppressor genes: comparative genomics and network perspectives.癌基因与肿瘤抑制基因:比较基因组学与网络视角
BMC Genomics. 2015;16 Suppl 7(Suppl 7):S8. doi: 10.1186/1471-2164-16-S7-S8. Epub 2015 Jun 11.
6
Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome.累积的单倍体不足和三倍体敏感性驱动非整倍体模式,并塑造癌症基因组。
Cell. 2013 Nov 7;155(4):948-62. doi: 10.1016/j.cell.2013.10.011. Epub 2013 Oct 31.
7
SomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering.SomInaClust:基于失活和聚类的体细胞突变模式检测癌症基因。
BMC Bioinformatics. 2015 Apr 23;16:125. doi: 10.1186/s12859-015-0555-7.
8
IDENTIFY CANCER DRIVER GENES THROUGH SHARED MENDELIAN DISEASE PATHOGENIC VARIANTS AND CANCER SOMATIC MUTATIONS.通过共享的孟德尔疾病致病变异和癌症体细胞突变来鉴定癌症驱动基因。
Pac Symp Biocomput. 2017;22:473-484. doi: 10.1142/9789813207813_0044.
9
The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer.结直肠癌中肿瘤抑制基因、癌基因和微小RNA的共调控网络。
Genes Chromosomes Cancer. 2017 Nov;56(11):769-787. doi: 10.1002/gcc.22481. Epub 2017 Jul 30.
10
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.在癌症基因组中检测致癌和具有临床可操作性的突变,关键取决于变异调用工具。
Bioinformatics. 2022 Jun 13;38(12):3181-3191. doi: 10.1093/bioinformatics/btac306.

引用本文的文献

1
Competing Subclones and Fitness Diversity Shape Tumor Evolution Across Cancer Types.相互竞争的亚克隆和适应性多样性塑造了不同癌症类型的肿瘤进化。
bioRxiv. 2025 Jun 3:2025.05.31.657191. doi: 10.1101/2025.05.31.657191.
2
Novel Computational and Artificial Intelligence Models in Cancer Research.癌症研究中的新型计算与人工智能模型
Cancers (Basel). 2025 Jan 2;17(1):116. doi: 10.3390/cancers17010116.
3
Protein structural context of cancer mutations reveals molecular mechanisms and candidate driver genes.癌症突变的蛋白质结构背景揭示了分子机制和候选驱动基因。

本文引用的文献

1
Passenger Hotspot Mutations in Cancer.癌症中的乘客热点突变。
Cancer Cell. 2019 Sep 16;36(3):288-301.e14. doi: 10.1016/j.ccell.2019.08.002.
2
Detailed modeling of positive selection improves detection of cancer driver genes.详细的正选择建模可提高癌症驱动基因的检测能力。
Nat Commun. 2019 Jul 30;10(1):3399. doi: 10.1038/s41467-019-11284-9.
3
Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features.由 APOBEC3A 和中尺度基因组特征驱动的癌症中的乘客热点突变。
Cell Rep. 2024 Nov 26;43(11):114905. doi: 10.1016/j.celrep.2024.114905. Epub 2024 Oct 22.
4
An Overview of Research Advances in Oncology Regarding the Transcription Factor ATF4.肿瘤学中关于转录因子ATF4的研究进展综述
Curr Drug Targets. 2025;26(1):59-72. doi: 10.2174/0113894501328461240921062056.
5
Construction and clinical significance of prognostic risk markers based on cancer driver genes in lung adenocarcinoma.基于肺癌驱动基因的肺腺癌预后风险标志物的构建及其临床意义
Clin Transl Oncol. 2025 Apr;27(4):1539-1557. doi: 10.1007/s12094-024-03703-1. Epub 2024 Sep 18.
6
Copy number losses of oncogenes and gains of tumor suppressor genes generate common driver mutations.癌基因的拷贝数缺失和肿瘤抑制基因的获得会产生常见的驱动突变。
Nat Commun. 2024 Jul 20;15(1):6139. doi: 10.1038/s41467-024-50552-1.
7
Strength of selection in lung tumors correlates with clinical features better than tumor mutation burden.肺肿瘤中的选择强度与临床特征的相关性优于肿瘤突变负担。
Sci Rep. 2024 Jun 3;14(1):12732. doi: 10.1038/s41598-024-63468-z.
8
Oncogenes and tumor suppressor genes: functions and roles in cancers.癌基因与肿瘤抑制基因:在癌症中的功能与作用
MedComm (2020). 2024 May 31;5(6):e582. doi: 10.1002/mco2.582. eCollection 2024 Jun.
9
Genome-wide screening and functional validation of methylation barriers near promoters.全基因组范围内启动子附近甲基化障碍的筛选和功能验证。
Nucleic Acids Res. 2024 May 22;52(9):4857-4871. doi: 10.1093/nar/gkae302.
10
Prediction of cancer driver genes and mutations: the potential of integrative computational frameworks.预测癌症驱动基因和突变:集成计算框架的潜力。
Brief Bioinform. 2024 Jan 22;25(2). doi: 10.1093/bib/bbad519.
Science. 2019 Jun 28;364(6447). doi: 10.1126/science.aaw2872.
4
First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive Mutation-Positive Non-Small Cell Lung Cancer?初治 EGFR 突变阳性非小细胞肺癌一线应用一代、二代 EGFR-TKI 后全部替换为奥希替尼治疗?
Int J Mol Sci. 2019 Jan 3;20(1):146. doi: 10.3390/ijms20010146.
5
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers.COSMIC 癌症基因目录:描述所有人类癌症中的遗传功能障碍。
Nat Rev Cancer. 2018 Nov;18(11):696-705. doi: 10.1038/s41568-018-0060-1.
6
The effects of mutational processes and selection on driver mutations across cancer types.突变过程和选择对不同癌症类型驱动突变的影响。
Nat Commun. 2018 May 10;9(1):1857. doi: 10.1038/s41467-018-04208-6.
7
Comprehensive Characterization of Cancer Driver Genes and Mutations.全面描绘癌症驱动基因和突变。
Cell. 2018 Apr 5;173(2):371-385.e18. doi: 10.1016/j.cell.2018.02.060.
8
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.癌症基因组图谱中 MYC 癌基因及其近端网络在多种癌症中的改变
Cell Syst. 2018 Mar 28;6(3):282-300.e2. doi: 10.1016/j.cels.2018.03.003.
9
EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.表皮生长因子受体作为胶质母细胞瘤治疗靶点:一个未兑现的承诺。
CNS Drugs. 2017 Sep;31(9):723-735. doi: 10.1007/s40263-017-0456-6.
10
Comparison of algorithms for the detection of cancer drivers at subgene resolution.亚基因分辨率下癌症驱动基因检测算法的比较
Nat Methods. 2017 Aug;14(8):782-788. doi: 10.1038/nmeth.4364. Epub 2017 Jul 17.